Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LipiGesic M is an over-the-counter, homeopathic combination drug formulated as a sublingual (under-the-tongue) gel containing feverfew and ginger. It is designed for the acute treatment of migraine headaches and associated symptoms. The sublingual delivery system allows for rapid absorption directly into the bloodstream, bypassing gastrointestinal breakdown and potentially leading to faster onset of action. Clinical studies have shown that LipiGesic M can reduce or eliminate migraine pain in at least 64% of occurrences, with a favorable safety profile—no serious adverse events or significant drug interactions reported. Its mechanism of action is believed to be related to the anti-inflammatory and vasoprotective effects of its active ingredients, which may inhibit prostaglandin synthesis and modulate vascular tone. Developed by PuraMed BioScience, LipiGesic M has been recognized by headache experts as an excellent first-line therapy for early intervention in acute migraine attacks[1][2][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on LipiGesic M.